Experimental vaccine extends survival in late-stage AML

CANCER DIGEST – Nov. 21, 2026 – A new therapeutic vaccine significantly extended the lives of patients with acute myeloid leukemia (AML) who are unable to undergo stem cell transplants, according to preliminary trial results released by the pharmaceutical company Sellas Life Sciences.
Although rare overall, AML is one of the most common types of blood cancer. It typically progresses aggressively and often requires harsh, treatment with chemotherapy, sometimes followed by a bone marrow transplant. Even when these therapies stop the cancer, AML often returns, and treatment options for relapsed AML have been limited.
This trial is testing a new vaccine, galinpepimut-S (or GPS), developed by David A. Scheinberg, MD, PhD, at Memorial Sloan Kettering Cancer Center (MSK). The drug differs from other cancer vaccines in that it is ready-made and can be used "off-the-shelf" as opposed to vaccines that use a personalized approach.
Such personalized vaccines are typically made by removing a patient’s immune cells that are shown to be attacking the cancer, growing them into billions in the lab, and re-infusing them into the patient.
By contrast GPS is an engineered complex using synthetic "peptides" that trigger a targeted immune response. Because GPS doesn’t need to be custom-made for each patient it is hoped it can be mass produced and administered to any patient with AML.
The early results of the Phase III clinical trial announced by the drugmaker involved outcomes of 126 AML patients in their second or later remission, meaning they had seen the cancer halted temporarily by previous treatments, only to have the disease resume progression. In this trial the patients had relapsed at least twice prior to enrolling.
In the trial, patients were randomly assigned to treatment with half receiving the GPS vaccine, and half receiving standard treatments.
The early results showed that patients who received GPS had their risk of death cut by 41% compared to the standard treatment group, and survived for a median of 24 months, compared with 14.7 months for those in the standard treatment group.
“Two decades of research have given us a much clearer picture of how the immune system can recognize and attack tumors and leukemias,” Dr. Scheinberg said in a press release. “These insights are helping lay the groundwork for these exciting, new immune-based approaches that could safely benefit more people with cancer. These data bring us closer to having the first off-the-shelf vaccine for AML patients.”
It is important to note that these preliminary results from the ongoing trial have not been peer-reviewed and published in medical journal. Also, Dr. Scheinberg and Memorial Sloan Kettering have financial interests in the drugmaker SELLAS Life Sciences.
Sources: Memorial Sloan Kettering press release




















Comments